Physician profile
Jered Jacob Weinstock
NPI 1952750572
$70,728.79
in general payments reported to CMS, 2019-2025
33 companies · $16K in 2025
The $16K reported for 2025 was more than what 97% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2021: $271 · 2022: $1,848 · 2023: $12K · 2024: $41K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $13K · Food and Beverage: $7,268 · Consulting Fee: $1,885 · Gift: $725 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,791.80 |
| Travel and Lodging | $12,631.40 |
| Food and Beverage | $7,267.62 |
| Consulting Fee | $1,885.00 |
| Gift | $725.00 |
| Education | $205.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $61,298.36 | 2022-2025 | Dupixent |
| Insmed, INC. | $1,405.41 | 2021-2025 | Brinsupri, Arikayce |
| Sekisui Diagnostics LLC | $1,240.00 | 2022-2025 | |
| Baxter Healthcare | $1,206.10 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Synclara Cough System |
| Astrazeneca Pharmaceuticals Lp | $1,187.66 | 2023-2025 | Tezspire, Fasenra |
| Zoll Medical Corporation | $991.67 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $507.88 | 2022-2025 | Trikafta |
| Genzyme Corporation | $364.95 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $285.00 | 2023 | |
| Cipla USA INC. | $215.00 | 2025 | |
| Electromed, INC. | $210.97 | 2025 | Smartvest |
| Erbe USA INC | $189.73 | 2025 | Erbecryo2/Vio3/Apc3 |
| Genentech USA, INC. | $171.15 | 2021-2025 | Xolair |
| Biogen, INC. | $165.95 | 2023-2024 | Spinraza |
| Fisher & Paykel Healthcare INC | $158.34 | 2023 | Fisher & Paykel Healthcare |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $129.83 | 2024 | Tobi Podhaler |
| Regeneron Pharmaceuticals, INC. | $124.99 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $120.92 | 2019-2023 | Nucala |
| Catalyst Pharmaceuticals, INC. | $108.00 | 2025 | |
| Viatris Specialty LLC | $96.11 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $90.10 | 2023 | |
| Springworks Therapeutics, INC. | $90.00 | 2025 | Gomekli |
| Amgen INC. | $80.60 | 2023 | Tezspire |
| Philips North America LLC | $64.26 | 2019-2022 | |
| Becton, Dickinson and Company | $49.00 | 2023 | Bd Nexiva |
| Sentynl Therapeutics, INC. | $40.00 | 2022 | |
| Chiesi USA, INC. | $36.43 | 2022 | |
| Abbvie INC. | $27.60 | 2021-2024 | |
| Circassia INC. | $19.97 | 2019 | |
| Gilead Sciences, INC. | $19.69 | 2022 | |
| Neurelis, INC. | $18.44 | 2024 | Valtoco |
| Novartis Pharmaceuticals Corporation | $14.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jered Weinstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.